Back to Search
Start Over
Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation
- Source :
- Patel, P, Gupta, P K C, White, C M J, Stanley, A G, Williams, B & Tomaszewski, M 2016, ' Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation ', Journal of Human Hypertension, vol. 30, no. 6, pp. 368-73 . https://doi.org/10.1038/jhh.2015.103, https://doi.org/10.1038/jhh.2015.103, Journal of Human Hypertension
- Publication Year :
- 2016
-
Abstract
- Renal denervation is a potential therapeutic option for resistant hypertension. A thorough clinical assessment to exclude reversible/spurious causes of resistance to antihypertensive therapy is required prior to this procedure. The extent to which non-adherence to antihypertensive treatment contributes to apparent resistance to antihypertensive therapy in patients considered for renal denervation is not known. Patients (n=34) referred for renal denervation entered the evaluation pathway that included screening for adherence to antihypertensive treatment by high-performance liquid chromatography-tandem mass spectrometry-based urine analysis. Biochemical non-adherence to antihypertensive treatment was the most common cause of non-eligibility for renal denervation-23.5% of patients were either partially or completely non-adherent to prescribed antihypertensive treatment. About 5.9% of those referred for renal denervation had admitted non-adherence prior to performing the screening test. Suboptimal pharmacological treatment of hypertension and 'white-coat effect' accounted for apparently resistant hypertension in a further 17.7 and 5.9% of patients, respectively. Taken together, these three causes of pseudo-resistant hypertension accounted for 52.9% of patients referred for renal denervation. Only 14.7% of referred patients were ultimately deemed eligible for renal denervation. Without biochemical screening for therapeutic non-adherence, the eligibility rate for renal denervation would have been 38.2%. Non-adherence to antihypertensive treatment and other forms of therapeutic pseudo-resistance are by far the most common reason of 'resistant hypertension' in patients referred for renal denervation. We suggest that inclusion of biochemical screening for non-adherence to antihypertensive treatment may be helpful in evaluation of patients with 'resistant hypertension' prior to consideration of renal denervation.
- Subjects :
- Male
medicine.medical_specialty
Urinalysis
Clinical Decision-Making
Drug Resistance
Blood Pressure
Drug resistance
030204 cardiovascular system & hematology
Kidney
Medication Adherence
03 medical and health sciences
Renal Artery
0302 clinical medicine
Predictive Value of Tests
Tandem Mass Spectrometry
Internal medicine
medicine.artery
Internal Medicine
medicine
Humans
030212 general & internal medicine
Sympathectomy
Renal artery
Referral and Consultation
Antihypertensive Agents
Chromatography, High Pressure Liquid
Aged
Retrospective Studies
Denervation
medicine.diagnostic_test
business.industry
Patient Selection
Retrospective cohort study
Middle Aged
Surgery
medicine.anatomical_structure
Blood pressure
Predictive value of tests
Hypertension
Female
Original Article
Drug Monitoring
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Patel, P, Gupta, P K C, White, C M J, Stanley, A G, Williams, B & Tomaszewski, M 2016, ' Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation ', Journal of Human Hypertension, vol. 30, no. 6, pp. 368-73 . https://doi.org/10.1038/jhh.2015.103, https://doi.org/10.1038/jhh.2015.103, Journal of Human Hypertension
- Accession number :
- edsair.doi.dedup.....31800acd493ca9e8a81707d8363aa5c7
- Full Text :
- https://doi.org/10.1038/jhh.2015.103